Welcome Daubers! I had Cabel ask Leo on the status
Post# of 72440
“With the positive observation of intra-tumor p53 modulation, the Company will now allocate resources to focus its efforts on completing development of an oral formulation, including performing bridging toxicology work.”
http://www.ipharminc.com/press-release/2018/2...3-observed